Antiepileptic Drugs – Current Use

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques

Volumn 23, Issue S2, 1996, Pages S18-S23

  Wilder, B J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENYTOIN; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN;

CONFERENCE PAPER; EPILEPSY; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

ANTICONVULSANTS; CARBAMAZEPINE; EPILEPSY; HUMANS; PHENYTOIN; VALPROIC ACID;

EID: 0029906216     PISSN: 03171671     EISSN: 20570155     Source Type: Journal    
DOI: 10.1017/S031716710002093X     Document Type: Article

References (46)

1. Data from Pharmaceutical Manufactures Association, April, 1995.
2. Macdonald RL. Carbamazepine: mechanisms of action. In: RH Levy, RH Mattson, and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 491-498.
3. Loiseau P, Duche B. Carbamazepine: clinical use. In: RH Levy, RH Mattson, and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 555-566.
4. Holmes G: Carbamazepine: toxicity. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 567-579.
5. Morselli PL. Carbamazepine: absorption, distribution and excretion. In: RH Levy, RH Mattson and BS Meldrum. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 515-528.
6. Levy RH, Wurden CJ. Carbamazepine: interaction with other drugs. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995:543-554.
7. Yayer P, Cash DC, Maitre M. Is the anticonvulsant action of valproate linked to its Interaction with the Cerebral gamma hydroxybutrate system? Trends Pharmacol Sci 1988; 9:127-129.
8. Bourgeois BFD. Valproic acid: clinical use. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 633-639.
9. Mattson RH, Cramer JA, Collins JF and the DVA Epilepsy Coop. No. 264 Study Group. A comparison of valproate with carbamazepine for the treatment of complex seizures and secondary generalized tonic-clonic seizures in adults. N. Engl. J. Med. 1992;327:765-771.
10. Wilder BJ. Unpublished Data.
11. Dreifuss FE. Valproic acid: toxicity. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 641-648.
12. Levy RH, Shen DD. Valproic acid: absorption, distribution and excretion. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995:605-617.
13. Scheyer RD, Mattson RH. Valproic acid: interactions with other drugs. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995:621-631.
14. Davis R, Peters DH, McTavish D. Valproic acid. Drugs 1994; 47(2): 333-372.
15. Taylor CP. Gabapentin: mechanisms of action. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 829-841.
16. Chadwick D. Gabapentin: clinical use. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995, pp 851-856.
17. Ramsay RE, Wilder BJ. Unpublished data.
18. Ramsay RE. Gabapentin: toxicity. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995, 857-860.
19. McLean MJ. Gabapentin: chemistry, absorption, distribution and excretion. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995,843-849.
20. Mattson RH, Taylor C, McLean MJ, Ramsay RE. The role of gabapentin. Neurology 1994; 44 (Suppl 5): S1-S32.
21. Rogowski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental compounds. Pharmacol Rev 1990; 42: 223-286.
22. DeLorenzo R.J. Phenytoin: mechanisms of action. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 271-282.
23. Wilder BJ. Phenytoin: clinical use. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 339-344.
24. Spielberg SP, Gordon GB, Blake DA, Mellits ED, Bross DS. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol ExpTher 1981; 217: 386-389.
25. Strickler SM, Dansky LV, Miller MA, Seni MN, Anderman E. Genetic predisposition of phenytoin-induced birth defects. Lancet 1985;2:746-749.
26. Gailey E, Granstrom ML, Hiilesmaa V, Bardy A. Minor anomalies in the offspring of epileptic mothers. J Pediatr 1988a; 112: 520-529.
27. Gailey E, Kantola-Sorsa E, and Granstroni ML. Intelligence of children of epileptic mothers. J Pediatr 1988b; 113: 677-684.
28. Yerby MS. Teratogenicity of anticonvulsant medication. In: Pediatric Epilepsy Diagnosis and Therapy, EW Dodson and JM Pellock, eds. New York, Demos Publications, 1993: 265-279.
29. Brody MJ, Pellock JM. Taming the brain storms: felbamate updated. Lancet 1995;346:918-919.
30. Sofia RD. Felbamate: mechanisms of action. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 791-797.
31. Faught E, Sachdeo R, Rimler M, et al. Felbamate monotherapy for partial onset seizures: an active control study. Neurology 1993; 43: 688-692.
32. Felbamate Study Group in the Lennox-Gastaut Syndrome. N. Engl. J.Med. 1993;328:29-33.
33. Sachdeo R, Kramer LD, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-392.
34. Meldrum B. Leach M. The mechanism of action of lamotrigine. Rev Contemp Pharmacother 1994; 5: 107-114.
35. Mikati MA, Schacter SC, Schomer DL, Keally M, Osborne-Shafer P. Long-term tolerability, pharmacokinetic and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989; 12: 312-321.
36. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine thrapy for partial seizures: a multicenter placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35(1): 113-121.
37. Schlumberger E, Chavez, Palacios L. Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35(2): 359-367.
38. Dulac O. The use of lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133-139.
39. Binnie C.D. Lamotrigine. Epilepsia 1995; 36: S32.
40. Data from Glaxo Wellcome Safety Monitoring Group, 1995.
41. Richens A. Lamotrigine: toxicity. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 897-902.
42. Jung MJ, Palfreyman MG. Vigabatrin: mechanisms of action. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 903-913.
43. Kalviainen R, Mervaala E, Sivenius J, Riekkinen P.J. Vigabatrin: clinical use. RH Levy, RH Mattson and BS Meldrum, eds. In: Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 925-930.
44. Ben-Menachem E. Vigabatrin: chemistry, absorption, distribution, and elimination. In: RH Levy RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995:915-923.
45. Fisher RS, Kerrigan JF. Vigabatrin: toxicity. In: RH Levy, RH Mattson and BS Meldrum. eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 931-939.
46. Shorvon SD. Benzodiazepines: clobazam. In: RH Levy, RH Mattson and BS Meldrum, eds. Antiepileptic Drugs, Fourth Edition, New York, Raven Press, Ltd., 1995: 763-777.